The first data showing that RWJ 270201 is effective in humans with influenza virus infections were released recently. The data, presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Toronto, Canada; September 2000], show that the oral neuraminidase inhibitor is effective in treating both influenza A and B virus infections. RWJ 270201 is also well tolerated with no evidence of resistance. Meanwhile, Glaxo Wellcome and Roche also presented promising new data on their established neuraminidase inhibitors, zanamivir ['Relenza'] and oseltamivir ['Tamiflu'], respectively.